Incidence of intracardiac thrombus formation prior to electrical cardioversion in respect to the mode of oral anticoagulation.

Benjamin Schaeffer, Lea Rüden, Tim Salzbrunn, Hans O Pinnschmidt, Ruken Özge Akbulak, Julia Magdalena Moser, Mario Jularic, Christian Meyer, Christian Eickholt, Arian Sultan, Jakob Lüker, Daniel Steven, Stephan Willems, Boris Alexander Hoffmann

Journal: Journal of cardiovascular electrophysiology 2019;29(4):537-547

PMID: 29377448

Abstract

AIMS

To evaluate the incidence of newly diagnosed intracardiac thrombi (ICT) in respect to the mode of OAC in patients undergoing cardioversion (CV).

METHODS AND RESULTS

We prospectively assessed transesophageal echocardiography (TEE) and OAC therapy prior to CV in AF patients with ≥48-hour duration scheduled for CV. A total of 60 first-time ICT (4.7%) were diagnosed in 1,286 TEE, with highest rate in patients without OAC (9.6% vs. OAC 4.1%, P  =  0.009) and an apparently lower rate in nonvitamin K antagonist anticoagulants (NOAC) therapy compared to vitamin K antagonist (VKA) (2.5% vs. 5.3%, P  =  0.02). VKA therapy control 4 weeks prior to CV was overall average (time in therapeutic range 60%) and patients showed more frequently clinical characteristics and TEE parameters associated with risk for ICT. Even among patients with effective OAC therapy (uninterrupted NOAC and VKA therapy with international normalized ratio (INR) ≥2.0 for 3 weeks), ICT occurred in 2.7%, but with no difference between both groups (P  =  0.22). There was no difference between different types of NOAC. Independent predictors for ICT were history of embolism, hypertension, BMI, absence of OAC, renal function, reduced atrial appendage flow, and presence of spontaneous echo contrast.

CONCLUSION

NOAC therapy seems favorable in the overall prevention of ICT, although this is likely to be caused by suboptimal VKA therapy control and differences in the overall health status between VKA and NOAC patients. ICT occurred even with effective OAC therapy suggesting individual TEE-guided cardioversion in patients at risk.

© 2018 Wiley Periodicals, Inc.

Address: Department of Cardiology - Electrophysiology, University Hospital Hamburg, University Heart Center, Hamburg, Germany.; Department of Medical Biometry and Epidemiology, University Hospital Hamburg, Hamburg, Germany.; Department of Cardiology - Electrophysiology, University Hospital Cologne, Cologne, Germany.; Department of Cardiology - Electrophysiology, University Hospital Mainz, Mainz, Germany.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.